Document text
Principal Investigator: Margo A Brinton
Organization: EMORY UNIVERSITY
Fiscal Year: 2024
Award: $790,410
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
Flaviviruses are vector-borne, positive-stranded RNA viruses that emerge unexpectedly and cause a spectrum
of potentially severe diseases including hepatitis, vascular shock syndrome, encephalitis, paralysis, and
congenital abnormalities. During the last 70 years, Dengue (DENV), West Nile virus (WNV), and Zika virus (ZIKV)
epidemics have occurred globally, and flaviviruses infect over 400 million people annually. Despite extensive
research, there are currently no FDA approved antivirals available for any flavivirus infection. Vaccines exist for
Japanese encephalitis virus (JEV), Yellow Fever virus (YFV), and tick-borne encephalitis virus (TBEV); for
Dengue, Dengvaxia is for those previously infected, and Qdenga has received EU approval for all populations.
However, due to poor efficacy, low vaccination rates and sequence variability, cases due to flaviviruses still
remain high, justifying the need for antiviral development. Current antiviral drug development is focused on small
molecules and neutralizing antibodies, which require high doses or frequent re-dosing to obtain functional
outcomes; their efficacy has been challenged by virus sequence variations. Thus, it is crucial to address the
need for higher efficiency and broader spectrum antivirals. To address this need we are proposing a new
paradigm for antiviral development, a mRNA-encoded activatable RNase, Cas13, as a platform for flavivirus
treatment. Cas13 represents a programmable RNase that can directly target and degrade multiple viral RNAs.
Synthetic mRNA and lipid nanoparticles are being used to deliver the RNase, as it allows for transient, non-viral
delivery, with an improved safety profile over other gene therapy vectors. To date, our team was the first to
demonstrate efficacy of mRNA-encoded Cas13 in vivo against influenza and SARS-CoV-2 in our recent
publication in Nature Biotechnology. We also have preliminary data demonstrating single-dose efficacy using
mRNA-encoded Cas13 with DENV-2 via systemic LNP-based delivery. Our long-term goal is to generate a suite
of mRNA-encoded Cas13 drugs against pathogenic flaviviruses. Our short-term goal is to demonstrate targeting
of multiple flaviviruses, including DENV, WNV, ZIKV, Powassan and YFV, further investigate the mechanism of
action of Cas13, and demonstrate in vivo efficacy against DENV 1-4 and WNV.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Anti-viral Agents><Binding><Biotech><Biotechnology><Birth Defects><Blood Vessels><Brain Inflammation><Breakbone Fever Virus><COVID-19 virus><COVID19 virus><Cell Body><Cells><Chemistry><Circulatory Collapse><CoV-2><CoV2><Congenital Abnormality><Congenital Anatomical Abnormality><Congenital Defects><Congenital Deformity><Congenital Malformation><DENV><Data><Dengue><Dengue Virus><Dengue fever virus><Dengvaxia><Development><Disease><Disorder><Dose><Down-Regulation><Drug Delivery><Drug Delivery Systems><Drugs><Egypt 101 virus><Encephalitis><Enzyme Gene><Enzymes><FDA approved><Flavivirus><Flavivirus Infections><Formulation><Gene Therapy Vectors><Gene Transduction Agent><Gene Transduction Vectors><Goals><Grippe><Group B Arbovirus><Guide RNA><Hepatitis><Immunofluorescence><Immunofluorescence Immunologic><In Vitro><Infection><Influenza><Japanese B Encephalitis Virus><Japanese encephalitis virus><Life Cycle><Life Cycle Stages><Medication><Messenger RNA><Mice><Mice Mammals><Modeling><Molecular Interaction><Murine><Mus><Myelogenous><Myeloid><Nature><Non-Polyadenylated RNA><Orthoflavivirus><Palsy><Paralysed><Pathogenicity><Persons><Pharmaceutical Preparations><Plegia><Population><Powassan><Powassan virus><Publications><Qualifying><RNA><RNA Degradation><RNA Gene Products><RNA Nucleases><RNA Seq><RNA Viruses><RNA sequencing><RNAseq><RNase><Research><Resistance><Ribonuclease Family Protein><Ribonucleases><Ribonucleic Acid><Rodent><Rodentia><Rodents Mammals><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientific Publication><Seasons><Serotyping><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Shock><Syndrome><Tick-Borne Encephalitis Virus><Tickborne Encephalitis Virus><Time><Universities><Vaccination><Vaccines><Variant><Variation><Viral><Viral Diseases><Virus><Virus Diseases><Visceral><WNV><West Nile viral infection><West Nile virus><West Nile virus infection><Work><Wuhan coronavirus><Yellow Fever><Yellow fever virus><ZIKV><Zika Virus><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><circulatory shock><compare effectiveness><coronavirus disease 2019 virus><coronavirus disease-19 virus><deliver mRNA><deliver messenger RNA><delivery system for mRNA><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><drug efficacy><drug/agent><emergent virus><emerging virus><epidemic virus><functional outcomes><gRNA><hCoV19><improved><in vivo><in vivo Model><infected with West Nile virus><infection with West Nile virus><innovate><innovation><innovative><life course><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA delivery><messenger RNA delivery><mouse model><murine model><nCoV2><neurotropic><neutralizing antibody><nuclease><paralysis><paralytic><pathogen><prevent><preventing><resistant><response><shocks><single molecule><small molecule><solid state><superresolution imaging><transcriptome sequencing><transcriptomic sequencing><vascular><vector-borne><vectorborne><viral RNA><viral emergence><viral infection><virology><virus RNA><virus infection><virus-induced disease><zikav>